Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.56 |
| ▸ | CNR1 | P21554 | 9/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121914 | 1.00 | CNR2 (0.56) | CNR2CNR1ADAM17MMP1MMP2 | |
| SCHEMBL1174258 | 0.88 | CNR2 (0.72) | CNR2CNR1ADAM17 | |
| SCHEMBL1174256 | 0.88 | CNR2 (0.72) | CNR2CNR1ADAM17 | |
| SCHEMBL1174849 | 0.84 | CNR2 (0.79) | CNR2CNR1ADAM17MMP2MMP3 | |
| SCHEMBL1174846 | 0.84 | CNR2 (0.79) | CNR2CNR1ADAM17MMP2MMP3 | |
| SCHEMBL1174236 | 0.83 | CNR2 (0.63) | CNR2CNR1ADAM17MMP1MMP2 | |
| SCHEMBL1174234 | 0.83 | CNR2 (0.63) | CNR2CNR1ADAM17MMP1MMP2 | |
| SCHEMBL12883462 | 0.82 | CNR2 (0.53) | CNR2CNR1ADAM17 | |
| SCHEMBL4125569 | 0.82 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL4125566 | 0.82 | CNR2 (0.57) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | CNR2 2/4885CNR1 1/4885ADAM17 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.